74 related articles for article (PubMed ID: 33420997)
1. Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.
Wang X; Quarmby V; Ng C; Chuntharapai A; Shek T; Eigenbrot C; Kelley RF; Shia S; McCutcheon K; Lowe J; Leddy C; Coachman K; Cain G; Chu F; Hotzel I; Maia M; Wakshull E; Yang J
MAbs; 2013; 5(4):540-54. PubMed ID: 23774668
[TBL] [Abstract][Full Text] [Related]
2. Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.
Lotz GP; Lutz A; Martin-Facklam M; Hansbauer A; Schick E; Moessner E; Antony M; Stuchly T; Viert M; Hosse RJ; Freimoser-Grundschober A; Klein C; Schäfer M; Ritter M; Stubenrauch KG
Front Immunol; 2024; 15():1406353. PubMed ID: 38881900
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing Antibody: Biotherapeutic Modality-Based Review.
Gorovits B; Clements-Egan A; Birchler M; Liang M; Myler H; Peng K; Purushothama S; Rajadhyaksha M; Salazar-Fontana L; Sung C; Xue L
AAPS J; 2016 Mar; 18(2):311-20. PubMed ID: 26821802
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S
MAbs; 2021; 13(1):1898831. PubMed ID: 33729092
[TBL] [Abstract][Full Text] [Related]
5. Quantification of anti-drug antibodies against E6011, an anti-fractalkine monoclonal antibody, in monkey and human serum, by an electrochemiluminescence assay.
Aoyama M; Mano Y
J Pharmacol Toxicol Methods; 2023; 124():107470. PubMed ID: 37689367
[TBL] [Abstract][Full Text] [Related]
6. Automated Bioanalytical Workflow for Ligand Binding-Based Pharmacokinetic Assay Development.
Evans BR; Beck AG; Yeung L; Li A; Lee DH; Bateman KP; Chopra G
Anal Chem; 2024 Jan; 96(1):488-495. PubMed ID: 38156369
[TBL] [Abstract][Full Text] [Related]
7. Successful Development of Nonclinical Anti-Drug Antibody Assays to Support Zinpentraxin Alfa Reproductive Toxicology Studies.
Arjomandi A; Siradze K; Cheu M; Davancaze T; Yadav R; Rao GK; Wong L; Fischer SK
AAPS J; 2024 Jan; 26(1):16. PubMed ID: 38267613
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a Three-Way Comparability Assessment for a Bioanalytical Anti-Drug Antibody Method.
Kwok RS; Nijem I; Brady A; Hendricks R
AAPS J; 2024 Apr; 26(3):51. PubMed ID: 38637446
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies and Immunoassay for Medical Plant-Derived Natural Products: A Review.
Yan X; Zhao Y; Zhang Y; Qu H
Molecules; 2017 Feb; 22(3):. PubMed ID: 28245640
[TBL] [Abstract][Full Text] [Related]
10. A systematic examination of anti-drug antibody titer estimation: Applied recommendations.
Zhang L; Hodsdon ME; Pottanat T; Wang S; Konrad RJ; Seta N; Higgs RE
J Immunol Methods; 2023 Nov; 522():113569. PubMed ID: 37748729
[TBL] [Abstract][Full Text] [Related]
11. Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum.
Wilford T; Bartlett PD; Schlag A; Jasaitis L; Pandha H; Pierce AJ; Hughes R
Bioanalysis; 2024 Jul; ():1-13. PubMed ID: 38957926
[TBL] [Abstract][Full Text] [Related]
12. Frontier of therapeutic antibody discovery: The challenges and how to face them.
Lu ZJ; Deng SJ; Huang DG; He Y; Lei M; Zhou L; Jin P
World J Biol Chem; 2012 Dec; 3(12):187-96. PubMed ID: 23275803
[TBL] [Abstract][Full Text] [Related]
13. Value of drug level testing and antibody assays in optimising biological therapy.
Vermeire S; Gils A
Frontline Gastroenterol; 2013 Jan; 4(1):41-43. PubMed ID: 23293739
[No Abstract] [Full Text] [Related]
14. A bridging immunogenicity assay for anti-cabiralizumab antibodies: overcoming the low assay cut point and drug tolerance challenges.
Yuan L; Gleason CR; Stocker D; Li L; Shen JX; Ji QC
Bioanalysis; 2021 Mar; 13(5):395-407. PubMed ID: 33661021
[No Abstract] [Full Text] [Related]
15. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
Harth S; Frisch C
Methods Mol Biol; 2021; 2261():291-306. PubMed ID: 33420997
[TBL] [Abstract][Full Text] [Related]
16. Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
Harth S; Ten Haaf A; Loew C; Frisch C; Knappik A
MAbs; 2019 Jan; 11(1):178-190. PubMed ID: 30516449
[TBL] [Abstract][Full Text] [Related]
17. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of antigen mimicry by an anti-idiotope.
Fields BA; Goldbaum FA; Ysern X; Poljak RJ; Mariuzza RA
Nature; 1995 Apr; 374(6524):739-42. PubMed ID: 7536303
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
